AMLX
Amylyx Pharmaceuticals Inc.
$13.52
+$0.21(+1.54%)
91
Overall
--
Value
91
Tech
--
Quality
Market Cap
$1.07B
Volume
683.02K
52W Range
$2.60 - $13.50
Target Price
$14.88
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|
| REVENUE | |||||
| Total Revenue | $22.2M | $380.8M | $87.4M | ||
| Total Revenue | $22.2M | $380.8M | $87.4M | ||
| COST OF GOODS SOLD | |||||
| Cost of Revenue | $3.0M | $25.4M | $124.6M | ||
| GROSS PROFIT | |||||
| Gross Profit | $19.2M | $355.3M | $-37.3M | ||
| OPERATING EXPENSES | |||||
| Operating Expenses | $220.6M | $316.5M | $218.4M | ||
| Research & Development | $93.5M | $128.2M | $104.1M | ||
| Research Expense | $93.5M | $128.2M | $104.1M | ||
| Selling, General & Administrative | $127.1M | $188.4M | $114.3M | ||
| Selling & Marketing Expenses | $4.4M | $9.5M | $2.7M | ||
| General & Administrative Expenses | $127.1M | $188.4M | $114.3M | ||
| Promotion & Advertising | $4.4M | -- | -- | ||
| OPERATING INCOME | |||||
| Operating income | $-201.3M | $38.8M | $-314.7M | ||
| EBITDA | $-200.9M | $55.4M | $-301.2M | ||
| NON-OPERATING ITEMS | |||||
| Intinc | $4.3M | $16.2M | $13.8M | ||
| Net Non-Operating Interest Income/Expense | $4.3M | $16.2M | $13.8M | ||
| Other Income/Expense | $-551.0K | $660.0K | $1.2M | ||
| Other Special Charges | $-551.0K | $-660.0K | $-1.2M | ||
| SPECIAL ITEMS | |||||
| Restructring And Mn A Income | -- | -- | $22.9M | ||
| Special Income Charges | -- | -- | $-22.9M | ||
| PRE-TAX INCOME | |||||
| EBIT | $-201.3M | $54.3M | $-302.1M | ||
| Pre-Tax Income | $-197.6M | $54.3M | $-302.1M | ||
| INCOME TAX | |||||
| Tax Provision | $774.0K | $5.0M | $-393.0K | ||
| NET INCOME | |||||
| Net Income | $-198.4M | $49.3M | $-301.7M | ||
| Net Income (Continuing Operations) | $-198.4M | $49.3M | $-301.7M | ||
| Net Income (Discontinued Operations) | $-198.4M | $49.3M | $-301.7M | ||
| Net Income (Common Stockholders) | $-198.4M | $49.3M | $-301.7M | ||
| TOTALS | |||||
| Total Expenses | $223.6M | $342.0M | $343.0M | ||
| SHARE & EPS DATA | |||||
| Average Shares Outstanding | $58.5M | $67.2M | $68.1M | ||
| Average Shares Outstanding (Diluted) | $58.5M | $70.0M | $68.1M | ||
| Shares Outstanding | $66.7M | $67.8M | $88.6M | ||
| Basic EPS | $-3.39 | $0.73 | $-4.43 | ||
| Basic EPS (Continuing Operations) | $-3.39 | $0.73 | $-4.43 | ||
| Diluted EPS | $-3.39 | $0.70 | $-4.43 | ||
| Diluted EPS (Continuing Operations) | $-3.39 | $0.70 | $-4.43 | ||
| OTHER METRICS | |||||
| Other Gand A | $127.1M | $188.4M | $114.3M | ||
| Restruct | -- | -- | $22.9M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMLX | $13.52 | +1.5% | 683.02K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amylyx Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW